BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apixaban: Phase III data

Bristol-Myers and Pfizer reported data from the discontinued, double-blind, international Phase III APPRAISE-2 trial in 7,392 ACS patients showing that twice-daily 5 mg apixaban plus mono or dual antiplatelet therapy missed the primary endpoint of a significant difference in the proportion of patients with cardiovascular death, myocardial infarction or ischemic stroke at a median follow-up of 241 days vs. placebo (7.5% vs. 7.9%, p=0.51). Additionally, patients...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >